Pharvaris Analyst Price Targets - Benzinga

Pharvaris NV

PHVSNASDAQ

Trade with Public

Trade with Public

$30.89

-0.21-0.68%

最終更新: Oct 12, 4:39 PM

$30.50

-0.60-1.93%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Pharvaris Analyst Price Targets - Benzinga

Pharvaris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharvaris (PHVS).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

11Buy

1Hold

Consensus RatingOutperform# Analysts15Avg. Consensus PT$50Upside to Avg. PT+63.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$40→$44
Sep 9, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$46→$62
Sep 9, 2026	Leerink Partners	Joseph Schwartz	PT Raise	Outperform	$50→$65
Sep 9, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$55→$65
Sep 9, 2026	RBC Capital	Nevin Varghese	PT Raise	Outperform	$52→$62
Sep 9, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$75→$79
Sep 9, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$42→$50
Sep 8, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60
Sep 8, 2026	Wedbush	Laura Chico	Maintained	Outperform	$42
Aug 13, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$51→$52
Aug 13, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$39→$40
Aug 13, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$74→$75
Jul 15, 2026	Wells Fargo	Yanan Zhu	Initiate	Overweight	$55
Jun 25, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Overweight	$41→$46
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$75→$74
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$42
Apr 7, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$41→$42
Apr 6, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$52→$51
Mar 9, 2026	RBC Capital	Brian Abrahams	Initiate	Outperform	$52
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$60

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $40 to $44.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62

Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

Wells Fargo analyst Yanan Zhu maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $55 to $65.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62

RBC Capital analyst Nevin Varghese maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $52 to $62.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $75 to $79.

Benzinga Newsdesk